

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):  
December 6, 2017**

---

**MRI INTERVENTIONS, INC.**

**(Exact name of registrant as specified in its charter)**

**DELAWARE  
(State or other jurisdiction  
of incorporation)**

**001-34822  
(Commission  
File Number)**

**58-2394628  
(I.R.S. Employer  
Identification Number)**

**5 Musick  
Irvine, Ca. 92618  
(Address of principal executive offices, zip code)**

**(949) 900-6833  
(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 7.01. Regulation FD Disclosure**

On December 6, 2017, MRI Interventions, Inc. posted an updated investor presentation to its website at <http://ir.stockpr.com/mriinterventions/investor-presentation>. A copy of the investor presentation is being furnished herewith as Exhibit 99.1. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The information contained in Exhibit 99.1 is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make from time to time, by press release or otherwise. The Company undertakes no duty or obligation to publicly update or revise the information contained in this investor presentation, although it may do so from time-to-time as its management believes is warranted. Any such updating may be made through the filing or other reports or documents with the SEC, through press releases or other public disclosure.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibits are furnished herewith:

[Exhibit 99.1](#) Investor Presentation dated December 6, 2017.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 6, 2017

**MRI INTERVENTIONS, INC.**

By: /s/ Harold A. Hurwitz  
Harold A. Hurwitz  
Chief Financial Officer

---



# Investor Presentation

**Joe Burnett, President & CEO**

**December 6<sup>th</sup>, 2017**



---

## Forward Looking Statements

Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company's ability to obtain additional financing; estimates regarding the sufficiency of the Company's cash resources; future revenues from sales of the Company's ClearPoint® System products; and the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint System products. More detailed information on these and additional factors that could affect the Company's actual results are described in the “Risk Factors” section of the Company's Annual Report on Form 10-K for the year ended December 31, 2016, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, both of which have been filed with the Securities and Exchange Commission.



---

## MRIC: The Premier Company for Precision MRI-Guided Therapy

- **MRI Interventions: Leader in Precision MRI-Guided Therapy**
  - Unique Platform that allows surgeons and researchers to deliver devices and therapies to the brain with pinpoint accuracy under live MRI Guidance
  - Enables entire procedure to take place in the MRI suite and reduce the risk of hospital acquired infection and complications from moving open patients during surgery from the OR
  - Extensive Intellectual Property position: 70+ issued US patents, 45 international
- **Procedure Growth Fueled By Expanding Installed Base and Increased Utilization**
  - 52 Installed systems in the U.S. at leading Neurosurgery Hospitals and Teaching Programs
  - Each new system placement enables razor – razorblade disposable product sales
  - Procedure count continues to grow; 45% CAGR (est.) the past four years
  - Each procedure is supported by established direct sales channel of 15 territory managers and clinical specialists spread across the U.S.
- **Expanding Platform into Adjacent Areas to Address Additional Unmet Medical Needs**
  - Expanding platform into the stroke market for ICH via collaboration with Mayo Clinic
  - Evaluating global opportunities for expansion and sales leverage through direct and distributed partnerships
  - Existing and New addressable markets > \$1B in potential



## Without ClearPoint®, Minimally Invasive Neuro Procedures Are Performed “Blind”

### Conventional Stereotactic Procedure



No real time  
images – images  
from earlier in the  
day or week

### ClearPoint Neuro Procedure




## The ClearPoint Neuro Navigation System Platform

ClearPoint Procedure Overview:



ClearPoint Video  
*Entry and Trajectory*



ClearPoint Video  
*Alignment and Insertion*

[VIDEO](#)

[VIDEO](#)



## Our MRI-Guided Therapy Platform is Currently Being Used to:

### Implant Neuro Stimulation Products from:

- Medtronic
- St. Jude Medical
- NeuroPace
- Boston Scientific (Pending FDA Approval)



### Place Laser Ablation Probes from:

- Medtronic-Visualase
- Monteris Medical



### Deliver Drugs and Biologics from:

- Voyager
- Medicenna
- Oxford Biomedica
- International Stem Cell Corporation



### MRIC Platform Runs on All Major Scanners:

- Siemens
- GE
- Philips
- IMRIS



## Broad and Growing User Base of Leading Neurosurgeons

*ClearPoint® Is Installed in 52 Top US Hospitals and Growing*

*UC San Francisco  
San Francisco VA  
Stanford Univ  
UCSF Benioff Childrens  
USC  
UC San Diego  
Univ of Colo  
Univ of Utah  
Univ of Arizona  
Cook Children's  
MD Anderson  
Methodist Hosp  
Texas Children's Hosp  
Riverside  
Nationwide Children's  
Children's Mercy  
Kansas Univ Med Center  
Univ of Wisconsin  
Spectrum Health  
Ohio State Univ  
Univ of Cincinnati  
Univ of Michigan*






*Univ of Minnesota Med Ctr  
Brigham & Women's  
Boston Children's  
Yale Univ  
Univ of Pitt Med Center  
Memorial Sloan Kettering  
Hackensack Univ Med Center  
Cornell  
Central Du Page  
Nat. Institutes of Health  
Nat Children's Hospital  
Children's Hosp of Philadelphia  
Univ of Virginia  
Emory University  
Carillion  
Duke University  
Children's of Alabama  
CHOA Scottish Rite  
Willis Knighton  
Mayo Clinic Jacksonville  
Miami Children's*

**Strong Commercial Sales and Clinical Support Teams in Place**



# Precision MRI-Guided Platform: ClearPoint Neuro Navigation System

ClearPoint Components:

<b>Capital Sale</b>		<b>Recurring Revenue</b>
Reusable Hardware Components	Integrated Software	Single-Use, Disposable Components
		
<b>\$100K - \$175K ASP</b>		<b>~\$7,500 ASP Procedure</b>



Emory University Hospital




Univ. of California San Francisco  
Medical Center



Univ. of Pittsburgh  
Medical Center




## ClearPoint Neurosurgical Procedure Growth



- Q1, 2017:  
**146 Procedures**
- Q2, 2017:  
**162 Procedures**
- Q3, 2017:  
**161 Procedures**

# MRIC: 5-Year Growth Strategy



Target Indications of > 150,000 procedures per year represents  
**Potential Addressable Market for MRIC of \$1B+**



*Note: Market sizes for brain tumor, ICH are Pancreatic cancer are incidence numbers because of the nature of those diseases. Prevalence numbers are based on either market research conducted by a third party on behalf of MRI Interventions or research conducted by MRI Interventions of publicly available sources.*



# Existing Clinical Applications for Our ClearPoint System

*Complex and remote procedure where accuracy is paramount*



Electrode Placement and  
Biopsy

VIDEO

Laser Ablation

VIDEO

## Implant Neuro Stimulation Products from:

- Medtronic
- St. Jude Medical
- NeuroPace
- Boston Scientific (pending FDA Approval)



## Place Laser Ablation Probes from:

- Medtronic-Visualase
- Monteris Medical



- (1) Laser Ablation - MR Thermometry is an MRI-based functionality available on most MR scanner platforms and it is a feature built into products from several third party vendors. The ClearPoint system enables MRI-guided procedures and allows physicians to use this inherent MR capability during a procedure.
- (2) Drug Delivery - The SmartFlow® cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the ventricles during intracranial procedures. Delivery of other therapeutic agents, and delivery of agents to other areas of the brain, using the SmartFlow cannula is investigational.



## Existing Research Applications for Our ClearPoint System

*Drug Trials demand precise, efficient delivery to ensure the target is covered*

4

Drug Delivery

VIDEO

### Deliver Drugs and Biologics from:

- Voyager (Nasdaq:VYGR)
- Medicenna
- Oxford Biomedica
- International Stem Cell Corporation



(1) Laser Ablation - MR Thermometry is an MRI-based functionality available on most MR scanner platforms and it is a feature built into products from several third party vendors. The ClearPoint system enables MRI-guided procedures and allows physicians to use this inherent MR capability during a procedure.

(2) Drug Delivery - The SmartFlow® cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the ventricles during intracranial procedures. Delivery of other therapeutic agents, and delivery of agents to other areas of the brain, using the SmartFlow cannula is investigational.



## Expansion into Direct Therapy Markets including Stroke

### *Leveraging Existing Capabilities and Install Base*

5

#### **Initial Stroke Product (ClearAway™) Targets Intracerebral Hemorrhage (ICH)**


- Collaboration with Mayo Clinic
- Only major stroke subtype w/o clearly effective therapy – major unmet medical need
- Affects 80,000 to 100,000 people in the US each year

#### **Current Approaches for Hemorrhage Removal and Decompression are Inadequate:**

- Open craniotomy provides visibility but is highly invasive, destroys brain tissue
- Minimally invasive approach has very limited ability to quantify volume reduction of the hemorrhage or monitor subsequent bleeds

#### **Our Unique ClearAway™ Approach to ICH**


- Detailed, continuous, high resolution, 4-D visibility
- Minimally invasive approach
- 95% of current sites already have a stroke program





# Significant Pipeline of New Products and Indications

Sales Efficiency in U.S. and abroad will Expand with Broader Product Portfolio



◆ Regulatory Submission

■ Commercializing

I Phase I

II Phase II



## Expand Globally and Scale Current Business Model

*Grow profit per procedure as we leverage sales expense and expand gross margin*

6

### **Improve profit-per-procedure by leveraging existing sales infrastructure**

- Large sales expense comes from clinical specialist case coverage and travel
- Reduce travel expense by hiring new specialists in cities with ClearPoint® already installed and active
- Strive toward shorter procedure times to enable two procedures in same scanner day

### **Expand Gross Margin through continued procedure growth**

- Current facility and overhead capable of supporting 5x procedure kits per year
- Target GM expansion from 60% to 70% over next five years

### **Prioritize next international market to penetrate with ClearPoint and our SmartFlow® Drug Delivery Cannulas**

- Underlying DBS and Laser Ablation procedures expanding WW but slow to date
- Progression of drug therapy trials from phase I to phase III will create new demand
- New therapy products and cannulas can expand portfolio to get scale



## Addressable Markets for our MRI-Guided Therapy Platform

Potential addressable markets in excess of \$1B


	Functional Neurosurgery Market			Stroke	Oncology	Drug Delivery Market	
	Parkinsons	Epilepsy	Brain Tumor	ICH	Pancreas	Parkinson's	Brian Tumor
Prevalence	1,500,000	2,200,000	80,000	90,000	50,000	1,500,000	80,000
Annual Potential Procedures	12,500	28,000	15,000	13,500	12,500	25,000	26,000
Est. Average Selling Price	\$7,500	\$7,500	\$7,500	\$6,000	\$5,000	\$14,000	\$8,000
Annual Market Opportunity	\$93 Million	\$210 Million	\$112 Million	\$81 Million	\$62 Million	\$350 Million	\$208 Million



Note: Market sizes for brain tumor, ICH and Pancreatic cancer are incidence numbers because of the nature of those diseases. Prevalence numbers are based on either market research conducted by a third party on behalf of MRI Interventions or research conducted by MRI Interventions of publicly available sources.



## Consistent Revenue Growth Since 2013




- 75%+ of revenue from single-use disposables
- Disposable CAGR from 2013-2017: 30%+ (est)

### Other Results of Note:

- Installed at 52 of 250+ target US neurosurgery centers
- 2017 9-mos revenue \$5.4M
- 2016 12-mos revenue \$5.6M

## Cash Flow From Operations\*: 2015 – Q3, 2017



\*Excludes interest payments, non-cash compensation and financing costs

## Income Statement, Last 5 Quarters

	Quarter Ended				
	Sep-16	Dec-16	Mar-17	Jun-17	Sep-17
<b>Revenues:</b>					
Disposable product revenues	\$ 1,272	\$ 1,363	\$ 1,663	\$ 1,436	\$ 1,421
Reusable product revenues	309	224	259	457	208
<b>Total product revenues</b>	<b>1,581</b>	<b>1,587</b>	<b>1,922</b>	<b>1,893</b>	<b>1,629</b>
Service revenues	35	48	85	83	88
<b>Total revenues</b>	<b>1,616</b>	<b>1,635</b>	<b>2,007</b>	<b>1,976</b>	<b>1,717</b>
<b>Cost of sales</b>	<b>748</b>	<b>677</b>	<b>752</b>	<b>798</b>	<b>689</b>
<b>Gross profit</b>	<b>868</b>	<b>958</b>	<b>1,255</b>	<b>1,178</b>	<b>1,028</b>
<b>Gross margin</b>	<b>54%</b>	<b>59%</b>	<b>63%</b>	<b>60%</b>	<b>60%</b>
<b>Total operating expenses</b>	<b>2,578</b>	<b>2,748</b>	<b>2,608</b>	<b>3,000</b>	<b>2,355</b>
<b>Operating loss</b>	<b>(1,710)</b>	<b>(1,790)</b>	<b>(1,354)</b>	<b>(1,822)</b>	<b>(1,327)</b>





## Experienced Medical Device Management Team

### Management Team

Joseph Burnett	CEO	  
Peter Piferi	COO	  
Wendelin Maners	VP Sales & Marketing	 
Hal Hurwitz	CFO	 

### Board of Directors

<p><b>Joseph Burnett</b></p>   	<p><b>Kimble Jenkins, Chairman</b></p>  <b>Morgan Keegan</b> <small>Morgan Keegan &amp; Company, Inc.</small>	<p><b>John Fletcher</b></p>  <b>Managing Partner, Founder</b>	<p><b>Pascal Girin</b></p>  	<p><b>Timothy Richards</b></p>    <small>SHARING EXPERTISE</small>	<p><b>Maria Sainz</b></p>    	<p><b>Jack Spencer</b></p> 
--	--	---	---	--	--	--



---

## MRIC: Executive Summary

- Unique, Platform technology enabling minimally-invasive treatments for some of the most difficult and debilitating disorders
- Installed in 52 of 250+ leading Neurology centers in the U.S.
- 75%+ of current revenue from single-use, high-margin disposables
- Procedure volume has grown 45%+ CAGR from 2013-2017
- Pipeline of new revenue streams from improvements to existing products, inclusion in drug therapy trials, and launch of new therapy products in the next five years
- Total potential addressable market > \$1B for our products and pipeline
- Continued gross margin and sales leverage expanding profitability per procedure
- Strong cash position to fund Commercial and R&D initiatives
- Significant IP position and partnerships with leading clinical sites for development
- A passionate team of embedded scientists and specialists

